ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,644.11
-0.12%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Genprex Inc (GNPX)

  7. Genprex Inc (GNPX) Noticias

GNPX Genprex Inc

3.65
1.23 (50.83%)
31 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Genprex Inc GNPX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
1.23 50.83% 3.65 23:00:05
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.77 2.57 4.0899 3.11 2.42
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
30/5/202407:31PRNUSGenprex to Present at the 2024 BIO International Convention
20/5/202415:35EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/5/202415:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202407:31PRNUSGenprex Doses First Patient in Acclaim-3 Clinical Study of..
13/5/202407:31PRNUSGenprex Announces the Appointment of Jose A. Moreno Toscano..
09/5/202407:11EDGAR2Form 8-K - Current report
08/5/202417:08PRNUSGenprex Announces the Passing of its Co-Founder and Chief..
01/5/202407:31PRNUSGenprex to Present and Participate at Upcoming May Investor..
09/4/202407:31PRNUSGenprex Collaborators Report Positive Preclinical Data on..
03/4/202407:31PRNUSGenprex Expands Clinical Trial Sites for Acclaim-3 Clinical..
02/4/202407:31PRNUSGenprex Collaborators Publish Positive Preclinical Data with..
22/3/202415:10PRNUSGenprex Announces Closing of $6.5 Million Registered Direct..
19/3/202412:24PRNUSGenprex Announces $6.5 Million Registered Direct Offering..
19/3/202407:36PRNUSGenprex Announces $6.5 Million Registered Direct Offering..
12/3/202408:01PRNUSGenprex Receives Notice of Patent Grant for Korean Patent..
06/3/202408:18EDGAR2Form 8-K - Current report
06/3/202407:30PRNUSGenprex Collaborators to Present Positive Preclinical Data..
26/2/202407:45EDGAR2Form 8-K - Current report
21/2/202415:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202413:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202407:15PRNUSGenprex Expands Nonclinical Programs into New Therapeutic..
06/2/202406:30PRNUSGenprex to Present at Upcoming BIO CEO & Investor Conference
05/2/202407:15EDGAR2Form 8-K - Current report
05/2/202406:30PRNUSGenprex Announces First Patient Dosed in Phase 2a Expansion..
02/2/202406:30EDGAR2Form 8-K - Current report
31/1/202408:00EDGAR2Form 8-K - Current report
31/1/202407:42PRNUSGenprex Announces 1-for-40 Reverse Stock Split Effective..
05/1/202415:17EDGAR2Form 8-K - Current report
05/1/202406:00PRNUSGenprex Provides Business Update and Outlook for 2024
18/12/202315:35EDGAR2Form 8-K - Current report
13/12/202315:50EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/12/202315:44EDGAR2Form 8-K - Current report
14/11/202310:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202315:19EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
03/11/202315:16EDGAR2Form DEF 14A - Other definitive proxy statements
01/11/202306:30PRNUSGenprex to Present at BIO-Europe 2023 Conference
23/10/202316:01EDGAR2Form PRE 14A - Other preliminary proxy statements
23/10/202315:44EDGAR2Form 8-K - Current report
20/10/202306:30PRNUSGenprex to Host a Virtual Key Opinion Leader Event on..
04/10/202311:00PRNUSGenprex to Present Data on the Use of REQORSA® for the..
25/9/202315:20EDGAR2Form 8-K - Current report
21/9/202307:30GLOBEGenprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation..
20/9/202307:45IHNWPathways to Progress: How Orphan Drug Designation Sparks..
08/9/202315:20EDGAR2Form 8-K - Current report
07/9/202306:30PRNUSGenprex to Present at Upcoming September Investor Conference
01/9/202315:17EDGAR2Form 8-K - Current report
22/8/202306:30PRNUSGenprex Appoints Suzanne Thornton-Jones as Senior Vice..
21/8/202316:13EDGAR2Form 8-K/A - Current report: [Amend]

Su Consulta Reciente

NASDAQ
GNPX
Genprex
BOV
LAND3F
Terra Santa Propriedades... ON
TG
LYXI
Amundi MSCI Indonesia UC...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados